Mesenchymal stem cell content of human vertebral bone marrow

被引:45
作者
Ahrens, N
Tormin, A
Paulus, M
Roosterman, D
Salama, A
Krenn, V
Neumann, U
Scheding, S
机构
[1] Inst Transfus Med, D-13353 Berlin, Germany
[2] Dept Gen Visceral & Transplantat Surg, D-13353 Berlin, Germany
[3] Bone Marrow Transplantat, Dept Pediat, D-13353 Berlin, Germany
[4] Dept Pathol, Berlin, Germany
关键词
cadaveric vertebral bone marrow; organ transplantation; bone marrow transplantation; mesenchymal stem cells; CFU-F;
D O I
10.1097/01.tp.0000133305.81823.2a
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mesenchymal stem cells (MSCs) are capable of down-regulating alloimmune responses and promoting the engraftment of hematopoietic stem cells. MSCs may therefore be suitable for improving donor-specific tolerance induction in solid-organ transplantation. Cells from cadaveric vertebral bone marrow (V-BM),aspirated iliac crest-BM, and peripheral blood progenitor cells were compared. Cells were characterized by flow cytometry and colony assays. MSCs generated from V-BM were assayed for differentiation capacity and immunomodulatory function. A median 5.7 X 10(8) nucleated cells (NCs) were recovered per vertebral body. The mesenchymal progenitor, colony-forming unit-fibroblast, frequency in V-BM (11.6/10(5) NC, range: 6.0-20.0) was considerably higher than in iliac crest-BM (1.4/10(5) NC, range: 0.4-2.6) and peripheral blood progenitor cells (not detectable). MSC generated from V-BM had the typical MSC phenotype (CD105(pos)CD73(pos)CD45(neg)CD34(neg)), displayed multilineage differentiation potential, and suppressed alloreactivity in mixed lymphocyte reactions. V-BM may be an excellent source for MSC cotransplantation approaches.
引用
收藏
页码:925 / 929
页数:5
相关论文
共 10 条
[1]  
CASTROMALASPINA H, 1980, BLOOD, V56, P289
[2]   BONE-MARROW AUGMENTATION OF DONOR-CELL CHIMERISM IN KIDNEY, LIVER, HEART, AND PANCREAS ISLET TRANSPLANTATION [J].
FONTES, P ;
RAO, AS ;
DEMETRIS, AJ ;
ZEEVI, A ;
TRUCCO, M ;
CARROLL, P ;
RYBKA, W ;
RUDERT, WA ;
RICORDI, C ;
DODSON, F ;
SHAPIRO, R ;
TZAKIS, A ;
TODO, S ;
ABUELMAGD, K ;
JORDAN, M ;
FUNG, JJ ;
STARZL, TE .
LANCET, 1994, 344 (8916) :151-155
[3]   Current trends in hematopoietic stem cell transplantation in Europe [J].
Gratwohl, A ;
Baldomero, H ;
Horisberger, B ;
Schmid, C ;
Passweg, J ;
Urbano-Ispizua, A .
BLOOD, 2002, 100 (07) :2374-2386
[4]   Mesenchymal stem cells:: heading into the clinic [J].
Koç, ON ;
Lazarus, HM .
BONE MARROW TRANSPLANTATION, 2001, 27 (03) :235-239
[5]  
Lazarus H, 2000, BLOOD, V96, p392A
[6]   Heparinized cadaveric organ donors (HCOD) - A potential source of hematopoietic cells for transplantation and gene therapy [J].
Machalinski, B ;
Kijowski, J ;
Marlicz, W ;
Gontarewicz, A ;
Markiewski, M ;
Paczkowski, M ;
Kopkowski, A ;
Majka, M ;
Ostrowski, M ;
Ratajczak, MZ .
TRANSPLANTATION, 2001, 71 (07) :1003-1007
[7]  
RYBKA WB, 1995, TRANSPLANTATION, V59, P871
[8]   Analysis of CD34-expressing cells in clinical practice [J].
Serke, S ;
Beyer, J ;
Rick, O ;
Schwella, N ;
Meyer, O ;
Hildebrandt, M ;
Huhn, D .
VOX SANGUINIS, 1998, 74 :469-475
[9]   Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation [J].
Tse, WT ;
Pendleton, JD ;
Beyer, WM ;
Egalka, MC ;
Guinan, EC .
TRANSPLANTATION, 2003, 75 (03) :389-397
[10]   Therapeutic approaches for transplantation [J].
Waldmann, H .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (05) :606-610